Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HERNATA: Trastuzumab + Docetaxel vs Vinorelbine in HER2+ Breast Cancer
NCT00430001Phase 3Unknown
- Sponsor
- Danish Breast Cancer Cooperative Group
- Start
- May 2005
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of vinorelbine in HER2-positive breast cancer (2 arms), sponsored by Danish Breast Cancer Cooperative Group. Primary endpoint: Time to Progression. Status: unknown.
02
Drugs
vinorelbine
03
Conditions
HER2-positive breast cancer
Beyond the preview
Go deeper on NCT00430001.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00430001.